指南与共识呼吸衰竭与机械通气重症综合管理与镇静镇痛

2019-2020年新型冠状病毒(严重急性呼吸综合征冠状病毒2)大流行:美国学术国际医学学院-世界急诊医学学术委员会多学科COVID-19工作组联合共识文件

The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper.
指南 / 共识 · J Glob Infect Dis · 2020-05-22
一句话结论COVID-19由SARS-CoV-2经呼吸道飞沫和污染物传播,重症可进展为ARDS伴炎症细胞因子失控和多器官衰竭;截至本文发表尚无可靠的特异性治疗药物,已开发临床患者风险分层工具辅助决策。

本文为美国学术国际医学学院与世界急诊医学学术委员会多学科COVID-19工作组联合共识文件。SARS-CoV-2为新型β属冠状病毒,经呼吸道飞沫和污染物传播,临床表现为发热、乏力、肌痛、结膜炎、嗅觉丧失、味觉障碍、咽痛、鼻塞、咳嗽、呼吸困难、恶心、呕吐和/或腹泻。重症可进展为急性呼吸窘迫综合征伴炎症细胞因子失控和多器官衰竭。已开发临床患者风险分层工具以辅助决定检测、隔离、监测、通气支持和去向;尚无可靠的特异性治疗药物。

要点

  • SARS-CoV-2经呼吸道飞沫和污染物传播,临床可表现为发热、乏力、肌痛、结膜炎、嗅觉丧失、味觉障碍、咽痛、鼻塞、咳嗽、呼吸困难、恶心、呕吐和/或腹泻。
  • 重症可进展为急性呼吸窘迫综合征,伴炎症细胞因子失控和多器官衰竭。
  • 已开发临床患者风险分层工具,辅助决定检测、隔离、监测、通气支持和去向。
  • 截至本文发表,尚无可靠的特异性COVID-19治疗药物(包括一些可能有效的单药和多药方案)。
  • 个人防护装备和呼吸机严重短缺,加重了本已不堪重负的医疗系统压力。

适用人群与场景

  • 急诊科、医院、诊所场景中的COVID-19疑似或确诊患者,以及需要风险分层以决定检测、隔离、监测、通气支持和去向的患者。

红旗征与不能漏的情况

  • 重症可进展为急性呼吸窘迫综合征,伴炎症细胞因子失控和多器官衰竭。

研究设计与关键结果

  • 本文为美国学术国际医学学院与世界急诊医学学术委员会多学科COVID-19工作组联合共识文件,讨论当前科学状态、缓解策略、可能疗法、医护人员与政策制定者的伦理考量,以及应对这一演变中的全球威胁和最终回归「新常态」的经验教训。
  • 已开发临床患者风险分层工具,辅助决定检测、隔离、监测、通气支持和去向。
  • 截至本文发表,尚无可靠的特异性COVID-19治疗药物(包括一些可能有效的单药和多药方案);多种抗病毒药物和免疫调节剂的临床试验正在进行。
  • 个人防护装备和呼吸机严重短缺,加重了本已不堪重负的医疗系统压力;社交距离、隔离和激增容量方面的持续挑战推动了远程医疗和网络分诊等技术辅助照护策略的增加。

证据类型、等级与局限

  • 证据类型:多学科工作组联合共识文件。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 可使用临床患者风险分层工具辅助决定COVID-19患者的检测、隔离、监测、通气支持和去向。
  • 截至本文发表,尚无可靠的特异性COVID-19治疗药物,包括一些可能有效的单药和多药方案。

指南或共识出处

  • The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper,美国学术国际医学学院-世界急诊医学学术委员会多学科COVID-19工作组。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」,故未列出这些栏目;全文请点「阅读原文」。
  • 另有 2 条提炼内容因数值无法与原文逐一核对而未列出,请以原文为准。
英文原文(摘要)· 点击展开

What started as a cluster of patients with a mysterious respiratory illness in Wuhan, China, in December 2019, was later determined to be coronavirus disease 2019 (COVID-19). The pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel Betacoronavirus, was subsequently isolated as the causative agent. SARS-CoV-2 is transmitted by respiratory droplets and fomites and presents clinically with fever, fatigue, myalgias, conjunctivitis, anosmia, dysgeusia, sore throat, nasal congestion, cough, dyspnea, nausea, vomiting, and/or diarrhea. In most critical cases, symptoms can escalate into acute respiratory distress syndrome accompanied by a runaway inflammatory cytokine response and multiorgan failure. As of this article's publication date, COVID-19 has spread to approximately 200 countries and territories, with over 4.3 million infections and more than 290,000 deaths as it has escalated into a global pandemic. Public health concerns mount as the situation evolves with an increasing number of infection hotspots around the globe. New information about the virus is emerging just as rapidly. This has led to the prompt development of clinical patient risk stratification tools to aid in determining the need for testing, isolation, monitoring, ventilator support, and disposition. COVID-19 spread is rapid, including imported cases in travelers, cases among close contacts of known infected individuals, and community-acquired cases without a readily identifiable source of infection. Critical shortages of personal protective equipment and ventilators are compounding the stress on overburdened healthcare systems. The continued challenges of social distancing, containment, isolation, and surge capacity in already stressed hospitals, clinics, and emergency departments have led to a swell in technologically-assisted care delivery strategies, such as telemedicine and web-based triage. As the race to develop an effective vaccine intensifies, several clinical trials of antivirals and immune modulators are underway, though no reliable COVID-19-specific therapeutics (inclusive of some potentially effective single and multi-drug regimens) have been identified as of yet. With many nations and regions declaring a state of emergency, unprecedented quarantine, social distancing, and border closing efforts are underway. Implementation of social and physical isolation measures has caused sudden and profound economic hardship, with marked decreases in global trade and local small business activity alike, and full ramifications likely yet to be felt. Current state-of-science, mitigation strategies, possible therapies, ethical considerations for healthcare workers and policymakers, as well as lessons learned for this evolving global threat and the eventual return to a "new normal" are discussed in this article.

来源:J Glob Infect Dis,查看原文。版权归原作者所有。

参考来源

  1. Stawicki SP, Jeanmonod R, Miller AC, et al. The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper. J Glob Infect Dis. 2020. PMID: 32773996. doi:10.4103/jgid.jgid_86_20

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。